Live Blog: The FDA Advisory Panel For Rixaroxaban for ACS - Forbes

3:56: Nissen says that an alternative to improving ACS therapy with an anticoagulant is to use a better antiplatelet (ticagrelor, prasugrel). 3:53: Dean Follman appears to be more positive to the drug. Notes that its approval for other ...

Accumetrics Sees Significantly Increased Interest in VerifyNow P2Y12 Test as Plavix(R) Loses Patent Protection - Marketwatch

Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient(R)) and clopidogrel (Plavix(R))), and GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the VerifyNow System ...

Approval of Generic Clopidogrel a Boon for Patients or Payors? - familypracticenews.com

“It is possible that the large payers will require genetic or platelet function testing proof of poor clopidogrel responsiveness before they agree to pay for prasugrel or ticagrelor,” he said in an interview. Dr. Peter Kowey, professor of medicine at ...

Plavix's New Generic Status Could Be Boon for Patients - YAHOO!

In addition, new drugs are available that may be better than Plavix, Fonarow said. "Newer antiplatelet agents, such as prasugrel (Effient) and ticagrelor (Brilinta), have been shown to be more [effective] than clopidogrel, and for many patients these ...

Aggredyne Receives CE Mark for AggreGuideTM A-100 - Boston Globe

The AggreGuide system is an in-vitro diagnostic test that measures how sticky a patient’s platelets are and how well the patient is responding to antiplatelet medications such as aspirin, Plavix® (clopidogrel), Effient® (prasugrel) ...

FDA Approves Generic Versions of Plavix - US News and World Report

In addition, new drugs are available that may be better than clopidogrel, Fonarow said. "Newer antiplatelet agents, such as prasugrel [Effient] and ticagrelor [Brilinta], have been shown to be more effective] than clopidogrel, and for many ...

FDA Panel Rejects ACS Indication for Rivaroxaban - familypracticenews.com

Warfarin and three P2Y12 inhibitors – ticagrelor (Brilinta), prasugrel (Effient), and ticlopidine (Ticlid) – are approved for this indication. The results of the ATLAS trial were published in January 2012 (N. Engl. J. Med. 2012;366:9-19). The FDA is ...

Search Results heart disease - Business Standard

Ranbaxy launches Daiichi's heart disease drug in India 10-JUN-10 Ranbaxy Laboratories today launched a generic version of Prasugrel, used in treating heart diseases, from Daiichi Sankyo portfolio in India as part of strategy to launch drugs from the parent ...

"Germany Pharmaceuticals & Healthcare Report Q2 2012" Now Available at Fast Market Research - SBWire

and Eli Lilly/Daiichi Sankyo's Effient (prasugrel). - In January 2012, in negative news for multinational drugmakers Eli Lilly and Boehringer Ingelheim, Trajenta (linagliptin) for patients with type 2 diabetes did not pass the Institute for Quality and ...